Douglas CDMO was proud to participate in Outsourced Pharma’s Capacity Update Week, a digital event designed to provide an inside look at the capabilities and capacities of leading CDMOs. This interactive platform allows pharmaceutical and biotech companies to engage with industry experts, ask questions, and assess potential partnerships—all from the convenience of their computer.
As a fully integrated CDMO proudly based in New Zealand, Douglas CDMO offers end-to-end drug development and manufacturing services, specializing in formulating and commercially supplying innovative and generic high-potency small molecule softgels and liquids. Our capabilities extend to producing prescription drugs across key therapeutic areas, including dermatology, oncology, endocrinology and the central nervous system. Quality and service underpin our business, and we are committed to delivering exceptional results to our clients.
In this session, Lora Wallis, Head of Delivery – Pharma, and Peter Surman, Chief Scientific Officer, share insights into Douglas CDMO’s capabilities, flexible approach, and commitment to accelerating pharmaceutical innovation. Watch the recording below to learn how we help partners navigate complex formulation challenges and bring high-quality therapies to market efficiently.